Capricor Therapeutics Sued for Securities Law Violations
Investors are reminded of a class action lawsuit filed against Capricor Therapeutics. The suit alleges violations of securities laws.
LOS ANGELES – Investors have been notified of a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The suit alleges violations of securities laws related to the company's business operations. DJS Law Group has announced it is reminding investors of the filed lawsuit. Specifically, the allegations center on purported violations of the U.S. Securities and Exchange Commission's (SEC) regulations, including sections §10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. Details of the lawsuit and the specific allegations are available in court filings. Investors who may have incurred losses due to a decline in the company's stock price following the emergence of these allegations are encouraged to contact the legal group for more information regarding their rights. Capricor Therapeutics is a biotechnology company focused on developing novel therapeutic treatments. The potential impact of these legal proceedings on the company's ongoing operations and future strategy will be closely monitored.